Canada First To OK Sanofi/Regeneron’s Sarilumab, But Struggle To Differentiate Looms
Sanofi/Regeneron’s Kevzara (sarilumab) has won its first worldwide approval for treating moderately to severely active rheumatoid arthritis from Health Canada. But as more regulators follow, the companies will face a battle to differentiate the drug from chief rival, Roche/Chugai’s Actemra (tocilizumab).
You may also be interested in...
FDA complete response letter seeks additional data on dosing and other safety concerns, delaying potential approval for an NDA that already had been pushed back three months. Interleukin-6 inhibitors sarilumab and sirukumab, now under review at FDA, both could obtain approval before baricitinib.
The latest drug development news and highlights from our FDA Performance Tracker.
The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.